Astrazeneca annual ebitda
2022
2023
2024
2025
Astrazeneca EBITDA Growth & History (AZN)
Astrazeneca's calculated EBITDA was $18.83B for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.83B | $4.10B | +27.87% |
| 2024 | 2024-12-31 | $14.72B | $1.87B | +14.57% |
| 2023 | 2023-12-31 | $12.85B | $3.77B | +41.46% |
| 2022 | 2022-12-31 | $9.09B | — | — |
Astrazeneca quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.16B | $208.0M | +4.20% |
| Q1 2026 | 2026-03-31 | $5.67B | — | — |
| Q4 2025 | 2025-12-31 | $4.38B | — | — |
| Q3 2025 | 2025-09-30 | $5.23B | — | — |
| Q2 2025 | 2025-06-30 | $4.96B | — | — |
Astrazeneca ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Astrazeneca's ebitda increased from $9.09B to $18.83B, a change of $9.74B. The latest reported quarter, Q2 2026, shows $5.16B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives priority review for perioperative bladder-cancer regimen
The FDA granted priority review to a regimen combining AstraZeneca ($AZN)’s Imfinzi with enfortumab vedotin around surgery for muscle-invasive bladder cancer in patients ineligible for, or declining, cisplatin chemotherapy. Imfinzi is given ...
AstraZeneca’s Klygefa receives a positive EU recommendation
European medicines advisers recommended AstraZeneca ($AZN)’s Klygefa, or gefurulimab, as an add-on to standard treatment for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The Alexion ...
Enhertu receives European recommendation for an earlier breast-cancer setting
European advisers recommended Enhertu for postoperative treatment of adults with HER2-positive breast cancer who still have invasive disease after preoperative taxane-based chemotherapy and HER2-directed treatment. The drug is jointly devel ...
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...
